Hexarelin (5 mg) is a synthetic hexapeptide growth hormone secretagogue derived from ghrelin-receptor-targeting peptide analogues. Researchers investigate it for its ability to stimulate pulsatile growth hormone release in both animal and human models. It is also researched for its broader effects on endocrine balance, metabolic regulation, and cardiovascular function. These properties make it a useful research compound in controlled experimental settings.

Hexarelin (5mg) is supplied as a lyophilized powder in a sealed vial. It is produced using research-grade synthesis methods, with purity and identity confirmed by techniques such as HPLC and mass spectrometry. The 5 mg format is suitable for small-scale studies, pilot experiments, and flexible dosing protocols in Hexarelin research.

Hexarelin (5mg) Key Features & Specs

• Subcategory: Muscle Growth & Performance Peptides
• Strength: 5 mg
• CAS: 140703-51-1
• Chemical Formula: C₄₇H₅₈N₁₂O₆
• Molecular Weight: 887.059 g/mol
• Peptide Sequence: His-2MeDTrp-Ala-Trp-DPhe-Lys-NH₂
• Synonyms: Examorelin

The compound is commonly utilized in Hexarelin growth hormone peptide studies focused on endocrine and metabolic signaling.

For laboratory research use only.

Hexarelin (5mg) Research Uses

Hexarelin is used to study the regulation of growth hormone secretion and the function of the hypothalamic-pituitary system. It is used to observe how hormone levels change in response to stimulation under controlled conditions.

Hexarelin has also been investigated in cardiovascular research, focusing on its effects on myocardial function, inflammation, oxidative stress, and structural changes in heart tissue, particularly under conditions like ischemia or cardiac stress.

In metabolic research, Hexarelin is studied for its potential effects on glucose regulation, lipid metabolism, and body composition. Ongoing research examines how it may influence energy balance and stress response pathways.

Hexarelin (5mg) Insights & Observed Findings

Human studies have reported dose-dependent increases in circulating growth hormone following single-dose administration of Hexarelin at microgram-per-kilogram levels. These responses are typically measured over short timeframes in experimental settings.

In preclinical animal studies, repeated dosing protocols (e.g., daily administration at 0.3 mg/kg) have been used to evaluate cardiovascular and metabolic parameters. Findings have included changes in cardiac function markers, reductions in inflammatory indicators, and modulation of oxidative stress.

Cell-based studies have shown that Hexarelin may influence cell survival, oxidative balance, and lipid handling under laboratory conditions. These findings support Hexarelin’s role as a research compound for studying endocrine and metabolic signaling.

Hexarelin (5mg) Handling & Storage

• Store Hexarelin (5mg) in its lyophilized form at approximately –20 °C in the original sealed vial. Protect the product from light and moisture to maintain its integrity.
• Allow the vial to reach room temperature before opening to reduce condensation.
• Reconstitution should be performed using a sterile, particle-free aqueous solution under aseptic conditions, with gentle mixing to avoid foaming.
• Reconstituted solutions intended for experimental work should be stored under refrigerated conditions (2–8 °C) and protected from light.
• Follow standard laboratory protocols for handling, storage, and disposal.

Compliance Notice: This product is intended for laboratory research use only and is not approved for human or veterinary use. It is not intended for diagnostic, therapeutic, or clinical applications. Any reference to biological activity or potential effects is based solely on preclinical or in-vitro findings and should not be interpreted as validated clinical outcomes. Researchers are responsible for ensuring proper handling, storage, and disposal in accordance with institutional, federal, and international guidelines.

References

1. Hexarelin. ScienceDirect. https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/hexarelin
2. Mosa R, Huang L, Wu Y, et al. Hexarelin, a Growth Hormone Secretagogue, Improves Lipid Metabolic Aberrations in Nonobese Insulin-Resistant Male MKR Mice. Endocrinology. 2017;158(10):3174-3187. doi:10.1210/en.2017-00168
3. McDonald H, Peart J, Kurniawan N, et al. Hexarelin treatment preserves myocardial function and reduces cardiac fibrosis in a mouse model of acute myocardial infarction. Physiol Rep. 2018;6(9):e13699. doi:10.14814/phy2.13699
4. Giusti M, Foppiani L, Ponzani P, Cuttica CM, Falivene MR, Valenti S. Hexarelin is a stronger GH-releasing peptide than GHRH in normal cycling women but not in anorexia nervosa. J Endocrinol Invest. 1997;20(5):257-263. doi:10.1007/BF03350297
5. Berti F, Müller E, De Gennaro Colonna V, Rossoni G. Hexarelin exhibits protective activity against cardiac ischaemia in hearts from growth hormone-deficient rats. Growth Horm IGF Res. 1998;8 Suppl B:149-152. doi:10.1016/s1096-6374(98)80041-5
6. Mao Y, Tokudome T, Kishimoto I. The cardiovascular action of hexarelin. J Geriatr Cardiol. 2014;11(3):253-258. doi:10.11909/j.issn.1671-5411.2014.03.007
7. Bellone J, Bartolotta E, Sgattoni C, et al. Hexarelin, a synthetic GH-releasing peptide, is a powerful stimulus of GH secretion in pubertal children and in adults but not in prepubertal children and in elderly subjects. J Endocrinol Invest. 1998;21(8):494-500. doi:10.1007/BF03347334